English
简体中文
Total: £ 56.28
Published Date: 2025-04-24 | Pages: 83 | Tables: 85 | Pharma & Healthcare
The global market for Onychomycosis (Tinea Unguium) Drug was valued at US$ 3677 million in the year 2024 and is projected to reach a revised size of US$ 5427 million by 2031, growing at a CAGR of 5.8% during the forecast period.
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.
North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.
In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.
This report aims to provide a comprehensive presentation of the global market for Onychomycosis (Tinea Unguium) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Onychomycosis (Tinea Unguium) Drug.
The Onychomycosis (Tinea Unguium) Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Onychomycosis (Tinea Unguium) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Onychomycosis (Tinea Unguium) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Yangtze River
Torrent Pharma
J&J
Chengdu Brilliant
Novartis
Qilu Pharmaceutical
Xiuzheng Pharmaceutical
Hubei Hengan
TARO
Perrigo
Galderma pharm
Zhejiang Deyer
Valeant Pharma
Moberg
Segment by Type
Oral Medication
External Medicine
Segment by Application
Age under 18
Age 18-50
Age above 50
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Onychomycosis (Tinea Unguium) Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Medication
1.2.3 External Medicine
1.3 Market by Application
1.3.1 Global Onychomycosis (Tinea Unguium) Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Age under 18
1.3.3 Age 18-50
1.3.4 Age above 50
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Onychomycosis (Tinea Unguium) Drug Market Perspective (2020-2031)
2.2 Global Onychomycosis (Tinea Unguium) Drug Growth Trends by Region
2.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Onychomycosis (Tinea Unguium) Drug Historic Market Size by Region (2020-2025)
2.2.3 Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Region (2026-2031)
2.3 Onychomycosis (Tinea Unguium) Drug Market Dynamics
2.3.1 Onychomycosis (Tinea Unguium) Drug Industry Trends
2.3.2 Onychomycosis (Tinea Unguium) Drug Market Drivers
2.3.3 Onychomycosis (Tinea Unguium) Drug Market Challenges
2.3.4 Onychomycosis (Tinea Unguium) Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue
3.1.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue (2020-2025)
3.1.2 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Players (2020-2025)
3.2 Global Onychomycosis (Tinea Unguium) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Onychomycosis (Tinea Unguium) Drug Revenue
3.4 Global Onychomycosis (Tinea Unguium) Drug Market Concentration Ratio
3.4.1 Global Onychomycosis (Tinea Unguium) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Onychomycosis (Tinea Unguium) Drug Revenue in 2024
3.5 Global Key Players of Onychomycosis (Tinea Unguium) Drug Head office and Area Served
3.6 Global Key Players of Onychomycosis (Tinea Unguium) Drug, Product and Application
3.7 Global Key Players of Onychomycosis (Tinea Unguium) Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Type
4.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Type (2020-2025)
4.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Type (2026-2031)
5 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Application
5.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Application (2020-2025)
5.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Onychomycosis (Tinea Unguium) Drug Market Size (2020-2031)
6.2 North America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025)
6.4 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Onychomycosis (Tinea Unguium) Drug Market Size (2020-2031)
7.2 Europe Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025)
7.4 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size (2020-2031)
8.2 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Onychomycosis (Tinea Unguium) Drug Market Size (2020-2031)
9.2 Latin America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025)
9.4 Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size (2020-2031)
10.2 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Onychomycosis (Tinea Unguium) Drug Introduction
11.1.4 Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Yangtze River
11.2.1 Yangtze River Company Details
11.2.2 Yangtze River Business Overview
11.2.3 Yangtze River Onychomycosis (Tinea Unguium) Drug Introduction
11.2.4 Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.2.5 Yangtze River Recent Development
11.3 Torrent Pharma
11.3.1 Torrent Pharma Company Details
11.3.2 Torrent Pharma Business Overview
11.3.3 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Introduction
11.3.4 Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.3.5 Torrent Pharma Recent Development
11.4 J&J
11.4.1 J&J Company Details
11.4.2 J&J Business Overview
11.4.3 J&J Onychomycosis (Tinea Unguium) Drug Introduction
11.4.4 J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.4.5 J&J Recent Development
11.5 Chengdu Brilliant
11.5.1 Chengdu Brilliant Company Details
11.5.2 Chengdu Brilliant Business Overview
11.5.3 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Introduction
11.5.4 Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.5.5 Chengdu Brilliant Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Onychomycosis (Tinea Unguium) Drug Introduction
11.6.4 Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.6.5 Novartis Recent Development
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Details
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Introduction
11.7.4 Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.7.5 Qilu Pharmaceutical Recent Development
11.8 Xiuzheng Pharmaceutical
11.8.1 Xiuzheng Pharmaceutical Company Details
11.8.2 Xiuzheng Pharmaceutical Business Overview
11.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Introduction
11.8.4 Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.8.5 Xiuzheng Pharmaceutical Recent Development
11.9 Hubei Hengan
11.9.1 Hubei Hengan Company Details
11.9.2 Hubei Hengan Business Overview
11.9.3 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Introduction
11.9.4 Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.9.5 Hubei Hengan Recent Development
11.10 TARO
11.10.1 TARO Company Details
11.10.2 TARO Business Overview
11.10.3 TARO Onychomycosis (Tinea Unguium) Drug Introduction
11.10.4 TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.10.5 TARO Recent Development
11.11 Perrigo
11.11.1 Perrigo Company Details
11.11.2 Perrigo Business Overview
11.11.3 Perrigo Onychomycosis (Tinea Unguium) Drug Introduction
11.11.4 Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.11.5 Perrigo Recent Development
11.12 Galderma pharm
11.12.1 Galderma pharm Company Details
11.12.2 Galderma pharm Business Overview
11.12.3 Galderma pharm Onychomycosis (Tinea Unguium) Drug Introduction
11.12.4 Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.12.5 Galderma pharm Recent Development
11.13 Zhejiang Deyer
11.13.1 Zhejiang Deyer Company Details
11.13.2 Zhejiang Deyer Business Overview
11.13.3 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Introduction
11.13.4 Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.13.5 Zhejiang Deyer Recent Development
11.14 Valeant Pharma
11.14.1 Valeant Pharma Company Details
11.14.2 Valeant Pharma Business Overview
11.14.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Introduction
11.14.4 Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.14.5 Valeant Pharma Recent Development
11.15 Moberg
11.15.1 Moberg Company Details
11.15.2 Moberg Business Overview
11.15.3 Moberg Onychomycosis (Tinea Unguium) Drug Introduction
11.15.4 Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
11.15.5 Moberg Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral Medication
Table 3. Key Players of External Medicine
Table 4. Global Onychomycosis (Tinea Unguium) Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Onychomycosis (Tinea Unguium) Drug Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2020-2025)
Table 8. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region (2026-2031)
Table 10. Onychomycosis (Tinea Unguium) Drug Market Trends
Table 11. Onychomycosis (Tinea Unguium) Drug Market Drivers
Table 12. Onychomycosis (Tinea Unguium) Drug Market Challenges
Table 13. Onychomycosis (Tinea Unguium) Drug Market Restraints
Table 14. Global Onychomycosis (Tinea Unguium) Drug Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Onychomycosis (Tinea Unguium) Drug Market Share by Players (2020-2025)
Table 16. Global Top Onychomycosis (Tinea Unguium) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Onychomycosis (Tinea Unguium) Drug as of 2024)
Table 17. Ranking of Global Top Onychomycosis (Tinea Unguium) Drug Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Onychomycosis (Tinea Unguium) Drug Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Onychomycosis (Tinea Unguium) Drug, Headquarters and Area Served
Table 20. Global Key Players of Onychomycosis (Tinea Unguium) Drug, Product and Application
Table 21. Global Key Players of Onychomycosis (Tinea Unguium) Drug, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Onychomycosis (Tinea Unguium) Drug Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2020-2025)
Table 25. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Type (2026-2031)
Table 27. Global Onychomycosis (Tinea Unguium) Drug Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2020-2025)
Table 29. Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Application (2026-2031)
Table 31. North America Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2026-2031) & (US$ Million)
Table 46. Pfizer Company Details
Table 47. Pfizer Business Overview
Table 48. Pfizer Onychomycosis (Tinea Unguium) Drug Product
Table 49. Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Yangtze River Company Details
Table 52. Yangtze River Business Overview
Table 53. Yangtze River Onychomycosis (Tinea Unguium) Drug Product
Table 54. Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 55. Yangtze River Recent Development
Table 56. Torrent Pharma Company Details
Table 57. Torrent Pharma Business Overview
Table 58. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product
Table 59. Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 60. Torrent Pharma Recent Development
Table 61. J&J Company Details
Table 62. J&J Business Overview
Table 63. J&J Onychomycosis (Tinea Unguium) Drug Product
Table 64. J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 65. J&J Recent Development
Table 66. Chengdu Brilliant Company Details
Table 67. Chengdu Brilliant Business Overview
Table 68. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product
Table 69. Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 70. Chengdu Brilliant Recent Development
Table 71. Novartis Company Details
Table 72. Novartis Business Overview
Table 73. Novartis Onychomycosis (Tinea Unguium) Drug Product
Table 74. Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Qilu Pharmaceutical Company Details
Table 77. Qilu Pharmaceutical Business Overview
Table 78. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product
Table 79. Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 80. Qilu Pharmaceutical Recent Development
Table 81. Xiuzheng Pharmaceutical Company Details
Table 82. Xiuzheng Pharmaceutical Business Overview
Table 83. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product
Table 84. Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 85. Xiuzheng Pharmaceutical Recent Development
Table 86. Hubei Hengan Company Details
Table 87. Hubei Hengan Business Overview
Table 88. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product
Table 89. Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 90. Hubei Hengan Recent Development
Table 91. TARO Company Details
Table 92. TARO Business Overview
Table 93. TARO Onychomycosis (Tinea Unguium) Drug Product
Table 94. TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 95. TARO Recent Development
Table 96. Perrigo Company Details
Table 97. Perrigo Business Overview
Table 98. Perrigo Onychomycosis (Tinea Unguium) Drug Product
Table 99. Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 100. Perrigo Recent Development
Table 101. Galderma pharm Company Details
Table 102. Galderma pharm Business Overview
Table 103. Galderma pharm Onychomycosis (Tinea Unguium) Drug Product
Table 104. Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 105. Galderma pharm Recent Development
Table 106. Zhejiang Deyer Company Details
Table 107. Zhejiang Deyer Business Overview
Table 108. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product
Table 109. Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 110. Zhejiang Deyer Recent Development
Table 111. Valeant Pharma Company Details
Table 112. Valeant Pharma Business Overview
Table 113. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product
Table 114. Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 115. Valeant Pharma Recent Development
Table 116. Moberg Company Details
Table 117. Moberg Business Overview
Table 118. Moberg Onychomycosis (Tinea Unguium) Drug Product
Table 119. Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (2020-2025) & (US$ Million)
Table 120. Moberg Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
Table 124. Authors List of This Report
List of Figures
Figure 1. Onychomycosis (Tinea Unguium) Drug Picture
Figure 2. Global Onychomycosis (Tinea Unguium) Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Onychomycosis (Tinea Unguium) Drug Market Share by Type: 2024 VS 2031
Figure 4. Oral Medication Features
Figure 5. External Medicine Features
Figure 6. Global Onychomycosis (Tinea Unguium) Drug Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Onychomycosis (Tinea Unguium) Drug Market Share by Application: 2024 VS 2031
Figure 8. Age under 18 Case Studies
Figure 9. Age 18-50 Case Studies
Figure 10. Age above 50 Case Studies
Figure 11. Onychomycosis (Tinea Unguium) Drug Report Years Considered
Figure 12. Global Onychomycosis (Tinea Unguium) Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Onychomycosis (Tinea Unguium) Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Onychomycosis (Tinea Unguium) Drug Market Share by Region: 2024 VS 2031
Figure 15. Global Onychomycosis (Tinea Unguium) Drug Market Share by Players in 2024
Figure 16. Global Top Onychomycosis (Tinea Unguium) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Onychomycosis (Tinea Unguium) Drug as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Onychomycosis (Tinea Unguium) Drug Revenue in 2024
Figure 18. North America Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Onychomycosis (Tinea Unguium) Drug Market Share by Country (2020-2031)
Figure 20. United States Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Onychomycosis (Tinea Unguium) Drug Market Share by Country (2020-2031)
Figure 24. Germany Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Share by Region (2020-2031)
Figure 32. China Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Onychomycosis (Tinea Unguium) Drug Market Share by Country (2020-2031)
Figure 40. Mexico Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Share by Country (2020-2031)
Figure 44. Turkey Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Onychomycosis (Tinea Unguium) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 48. Yangtze River Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 49. Torrent Pharma Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 50. J&J Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 51. Chengdu Brilliant Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 53. Qilu Pharmaceutical Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 54. Xiuzheng Pharmaceutical Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 55. Hubei Hengan Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 56. TARO Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 57. Perrigo Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 58. Galderma pharm Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 59. Zhejiang Deyer Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 60. Valeant Pharma Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 61. Moberg Revenue Growth Rate in Onychomycosis (Tinea Unguium) Drug Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
